Chromogranin A is a Useful Marker in Japanese Patients with Pancreatic Neuroendocrine Tumors Abstract #814

Introduction: Although Chromogranin A (CgA) is known as a useful marker for pancreatic neuroendocrine tumors (pNET) in the West, the usefulness of CgA in Japanese patients with pNETs is unclear.
Aim(s): To assess the potential usefulness of CgA for diagnosing pNET in Japan.
Materials and methods: We evaluated the serum CgA level in 189 patients with various pancreatic diseases including with proven pNET (n=69), pancreatic cancer (PC) (n=50), chronic pancreatitis (CP) (n=50), autoimmune pancreatitis (n=20) and 112 healthy subjects (normals) by using a ELISA kit, Chromoa (Cis Bioassays, France).
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Masayuki Hijioka

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors
Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Masami Miki
Authors: Miki M, Ito T, Hijioka M, Kawabe K, ...
#1264 Efficacy and Safety of Sunitinib as Long-term Treatment in Japanese Patients with Advanced Pancreatic Neuroendocrine Tumors.
Introduction: The results from recent clinical trials have suggested the ethnical difference in antitumor activity of sunitinib against advanced pancreatic neuroendocrine tumors (PNET), which seemed to be higher in Japanese than those in Western patients.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Lingaku Lee
Authors: Lee L, Ueda K, Fujiyama T, Tachibana Y, ...
#626 Preliminary Results of a Nationwide Survey of Pancreatic Neuroendocrine Tumors in von Hippel–Lindau Disease in Japan
Introduction: von Hippel–Lindau disease (VHL) is an intractable disease characterized by various tumors including pancreatic neuroendocrine tumors (PNET).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. Hisato Igarashi
#1074 Usefulness of a Combination of a 48-Hour Fasting and a Glucagon Tolerance Test
Introduction: The 72-hour fasting test is the gold standard for the diagnosis of insulinoma. However, the test can become a burden for both patients and medical staff and, shortening the duration of fast has been attempted. There are several reports on the high sensitivity of fasting test but only a few reports on its specificity. An insulinoma can be localized using invasive tests such as endoscopic ultrasonography and selective arterial secretagogue injection test. Therefore, insulinoma detection with high specificity may be needed to avoid unnecessary examinations.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Keijiro Ueda
Authors: Ueda K, Lee L, Hijioka M, Igarashi H, ...
#323 Efficacy and Safety of Everolimus in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET): Japanese Subgroup Analysis of RADIANT-3
Introduction: Everolimus, an oral inhibitor of mTOR, significantly improved progression-free survival (PFS) v. placebo in a phase III trial (RADIANT-3) in patients with advanced pNET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Takuji Okusaka
Authors: Okusaka T, Ito T, Ikeda M, Tajima T, ...
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.